Corona Remedies Limited (NSE: CORONA, BSE: 544644) is an Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹14,481 Cr, it ranks #474 by market cap among the 6,197 Indian listed companies on FinBizNet, and #10 of 63 in Pharmaceuticals. At ₹2,335.00 (as of 16 Nov 2026), the share price is 14.1% below its 52-week high of ₹2,719.30 and 74.7% above its 52-week low of ₹1,336.60.
| Current Price | ₹2,335.00 |
|---|---|
| Market Cap | ₹14,481 Cr |
| NSE Symbol | CORONA |
| BSE Code | 544644 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 77.6 |
| Return on Equity | 24.79% |
| Return on Assets | 14.99% |
| 52-Week Range | ₹1,336.60 – ₹2,719.30 |
| 3-Month Price Change | +10.2% |
| Beta (1Y) | 0.08 |
| Dividend Yield | 0.43% |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.coronaremedies.com |
| Revenue | ₹441 Cr |
|---|---|
| Net Profit | ₹60 Cr |
| Net Margin | 13.7% |
| EPS (Basic) | ₹9.86 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Corona Remedies Limited reported revenue of ₹441 Cr in Q2 FY27, up 22.2% from ₹361 Cr in Q2 FY26 and up 4.4% from ₹422 Cr in Q1 FY27. It posted a net profit of ₹60 Cr for the quarter, against a net profit of ₹52 Cr in Q2 FY26 (up 15.3%). Across the 5 quarters from Q2 FY26 to Q2 FY27, quarterly revenue ranged from ₹342 Cr (Q3 FY26) to ₹441 Cr (Q2 FY27). The company was profitable in each of these 5 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹441 Cr | ₹60 Cr | 13.7% |
| Q1 FY27 | ₹422 Cr | ₹60 Cr | 14.2% |
| Q4 FY26 | ₹353 Cr | ₹45 Cr | 12.8% |
| Q3 FY26 | ₹342 Cr | ₹41 Cr | 12.1% |
| Q2 FY26 | ₹361 Cr | ₹52 Cr | 14.5% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 69.00% of Corona Remedies Limited's shares as of Sept 2026, unchanged from Dec 2025. Delivery averaged 44.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women’s healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.
1. Pharmaceuticals-This segment develops, manufactures, and markets products in women’s healthcare, cardio-diabeto, pain management, urology, and other areas, such as vitamin minerals and nutrients, and gastrointestinal and respiratory therapies. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Corona Remedies Limited | ₹14,481 Cr | 77.6 | 24.79% | ₹441 Cr | — |
Listed by market capitalisation. Ratios are shown for context only.
Corona Remedies Limited is trading at ₹2,335.00, with a market capitalisation of ₹14,481 Cr.
Corona Remedies Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Corona Remedies Limited has a P/E of 77.6 and a return on equity of 24.79%.
Corona Remedies Limited is listed on the NSE under the symbol CORONA and on the BSE under the scrip code 544644.
In Q2 FY27, Corona Remedies Limited reported revenue of ₹441 Cr and net profit of ₹60 Cr, with basic EPS of ₹9.86 (consolidated, parsed from the company's exchange filing).
Corona Remedies Limited reported revenue of ₹441 Cr in Q2 FY27, up 22.2% from ₹361 Cr in Q2 FY26 and up 4.4% from ₹422 Cr in Q1 FY27.
Promoters held 69.00% of Corona Remedies Limited's shares as of Sept 2026, unchanged from Dec 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.